We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

64 hedge funds and large institutions have $360M invested in Janux Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more call options, than puts

Call options by funds: $60K | Put options by funds: $10K

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

12% more funds holding

Funds holding: 57 → 64 (+7)

2% more capital invested

Capital invested by funds: $354M → $360M (+$6.28M)

3.39% less ownership

Funds ownership: 76.1% → 72.71% (-3.4%)

Holders
64
Holders Change
+7
Holders Change %
+12.28%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
27
Reduced
11
Closed
7
Calls
$60K
Puts
$10K
Net Calls
+$50K
Net Calls Change
+$30K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.78M
2
BlackRock
BlackRock
New York
+$1.06M
3
Morgan Stanley
Morgan Stanley
New York
+$990K
4
Cerity Partners
Cerity Partners
New York
+$527K
5
ZIM
Zacks Investment Management
Illinois
+$509K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$14.5M
2
Citadel Advisors
Citadel Advisors
Florida
-$2.69M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$1.18M
4
JP Morgan Chase
JP Morgan Chase
New York
-$1.13M
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$41.1K +$28.9K +3,337 +681%
Nisa Investment Advisors
52
Nisa Investment Advisors
Missouri
$29.1K +$23.2K +2,685 +10,740%
TRCT
53
Tower Research Capital (TRC)
New York
$19K +$3.98K +460 +35%
AIP
54
Ameritas Investment Partners
Nebraska
$18.3K – – –
Lazard Asset Management
55
Lazard Asset Management
New York
$18K +$579 +67 +4%
AB
56
Amalgamated Bank
New York
$17K -$1.55K -179 -10%
MLICM
57
Metropolitan Life Insurance Company (MetLife)
New York
$10.8K – – –
RCM
58
Raleigh Capital Management
North Carolina
$2.9K +$2.33K +270 New
AWM
59
Avior Wealth Management
Nebraska
$2.61K +$2.1K +243 New
FFO
60
Fortitude Family Office
Arizona
$2.54K +$2.05K +237 New
ASN
61
Advisory Services Network
Georgia
$1.44K +$1.16K +134 New
US Bancorp
62
US Bancorp
Minnesota
$966 – – –
AF
63
Allworth Financial
California
$601 +$484 +56 New
HNB
64
Huntington National Bank
Ohio
$11 +$9 +1 New
Bank of Montreal
65
Bank of Montreal
Ontario, Canada
– -$1.08M -98,429 Closed
WP
66
Woodline Partners
California
– -$864K -85,708 Closed
Renaissance Technologies
67
Renaissance Technologies
New York
– -$263K -26,100 Closed
XT
68
XTX Topco
Cayman Islands
– -$137K -13,636 Closed
TI
69
Trexquant Investment
Connecticut
– -$119K -11,773 Closed
CC
70
Corton Capital
Ontario, Canada
– -$111K -11,061 Closed
Qube Research & Technologies (QRT)
71
Qube Research & Technologies (QRT)
United Kingdom
– -$88K -8,735 Closed
1 2
3

JANX Hedge Fund Activity: Q4 2023 in Review

64 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q4 2023, worth a combined $360M — up 1.8% from $354M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new JANX positions and 7 closed out — a net gain of 7 holders — while 27 added to existing stakes and 11 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $1.78M. The largest seller was Fidelity Investments, cutting an estimated $14.5M.

  • 64 institutional investors held Janux Therapeutics (JANX) as of Q4 2023, up from 57 in Q3 2023.
  • Funds reported $360M of Janux Therapeutics stock for Q4 2023, up 1.8% quarter-over-quarter.
  • 14 funds opened new Janux Therapeutics positions in Q4 2023 and 7 closed out, a net change of +7 holders.
  • The largest Janux Therapeutics buyer in Q4 2023 was Adage Capital Partners, an estimated $1.78M added.
  • The largest Janux Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $14.5M sold.

Based on aggregated 13F filings for Q4 2023.